Use Able AI chat for product recommendations

SIVA1 Polyclonal antibody

SIVA1 Polyclonal Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, ELISA

CD27 binding protein, CD27-binding protein, CD27BP, SIVA, Siva 1

Formulation:  PBS, Azide, Glycerol
PBS, Azide, Glycerol
Conjugate:  Unconjugated
Unconjugated
Size/Concentration: 
SKU: 

-/ -

Freight/Packing: -

Quantity

Please visit your regions distributor:

Able AI
Able AI
What's the best dilution for SIVA1 in ?

Tested Applications

Positive WB detected inMOLT-4 cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:2000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

27119-1-AP targets SIVA1 in WB, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen

CatNo: Ag25748

Product name: Recombinant human SIVA1 protein

Source: e coli.-derived, PGEX-4T

Tag: GST

Domain: 1-68 aa of BC034562

Sequence: MPKRSCPFADVAPLQLKVRVSQRELSRGVCAERYSQEVFDPSGVASIACSSCVRAVDGKAVCGQCERA

Predict reactive species
Full Name SIVA1, apoptosis-inducing factor
Calculated Molecular Weight 175 aa, 19 kDa
Observed Molecular Weight 19 kDa
GenBank Accession NumberBC034562
Gene Symbol SIVA1
Gene ID (NCBI) 10572
RRIDAB_3742216
Conjugate Unconjugated
FormLiquid
Purification MethodAntigen affinity purification
UNIPROT IDO15304
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol, pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Protocols

Product Specific Protocols
WB protocol for SIVA1 antibody 27119-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

What published studies show

The SIVA1 Polyclonal antibody (catalog 27119-1-AP) has 1 citation in the journal Biomol Biomed. The cited research was published in 2026 and titled "Regulatory B cells and SIVA1-LAG3 immune suppression predict poor prognosis in prostate cancer" (Author: Weicheng Tian). The research field concerns cancer immunology and prostate cancer prognosis. The antibody was applied in Western blot on human samples with RNAi-based validation.

SpeciesApplicationTitle
humanWB

Biomol Biomed

Regulatory B cells and SIVA1-LAG3 immune suppression predict poor prognosis in prostate cancer.

Authors - Weicheng Tian
  • KD Validated
Loading...
||
New chat

Able®

正在加载,请稍候...